DNMT inhibitors (DNMTi) have shown promising results in ovarian cancer in preclinical models by enhancing IFNγ-mediated [72] and type-I interferon-mediated inflammatory responses [73]. The gene discussed is IFNG; the disease is ovarian carcinoma.